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Abstract
The emergence of Coronavirus Disease 2019 (COVID-19) in late 2019 has
brought great challenges to public health worldwide and, to date, there is no specific
approved therapeutic protocol. Therefore, this chapter will analyze types of inter-
vention for use in patients with COVID-19 developed by American researchers
from records made on the Clinical Trials platform. For the search strategy, key-
words “COVID-19” in the “Condition or Disease” section and “United States” in the
“Country” section were used. No filters were applied. Data were descriptively
analyzed. In total, 1,182 studies were obtained, of which 496 met the eligibility
criteria. Sample size ranged from 1 to 10,000 participants. Most studies involved
the age group of 18–64 years (48.6%). As for design, randomized type (80.5%),
parallel (75.6%), open designs (38.7%) and those with therapeutic purpose (88.3%)
were more frequent. Most clinical trials used the two-arm trial (67.3%), researched
drugs (64.8%), used placebo (55.2%) and were sponsored by pharmaceutical/bio-
technology companies (35.4%). Clinical trials developed by American researchers
on COVID-19 involve adult and elderly participants, with predominance of ran-
domized, parallel and open design, for therapeutic purposes and mostly evaluated
immunosuppressants or combinations of antivirals/immunosuppressants. The
drugs and biological products Remdesivir, Baricitinib in combination with
Remdesivir, Bamlanivimab and Etesevimab, REGEN-COV and COVID-19 conva-
lescent plasma were also used, authorized for emergency use.
Keywords: Clinical Trial, Evidence-Based Practice, Pharmaceutical Preparations,
Vaccines, COVID-19, Coronavirus Infection
1. Introduction
In March 2020, the World Health Organization (WHO) recognized Coronavirus
Disease 2019 (COVID-19) as a public health problem and declared the state of
pandemic contamination [1]. Since its detection in late 2019, in China, the newly
discovered virus, called SARS-CoV-2 [2] spread rapidly around the world with
cases, to date, in 223 countries, with more than 127 million infected individuals and
nearly 3 million deaths [3]. The region of Americas concentrates almost half of all
diagnosed individuals, with the United States being the most affected country,
totaling 30 million cases [3].
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SARS-CoV-2 belongs to a family of single-stranded, positive-sense and
enveloped RNA viruses, known as Coronaviridae [4], has high mutation rate and
rapid spread, with multiple mutations having appeared and spread during the
pandemic [5, 6]. The transmission of the virus occurs through droplets expelled by a
person with the disease or through contact with contaminated surfaces [7].
In general, patients with COVID-19 have fever, cough, myalgia, nausea, diar-
rhea, reduced smell and taste, as well as mild breathlessness [8]. In the most severe
cases, patients can develop Acute Respiratory Distress Syndrome (ARDS), heart
failure, shock and renal failure [9]. Elderly, obese and individuals with pre-existing
conditions, such as diabetes, hypertension, cardiovascular and pulmonary diseases,
cancer, chronic kidney disease, among others, have higher risk of progressing to
more critical cases of the disease [10]. In addition to symptoms and severity of the
disease, the impact of COVID-19 affects all aspects of our lives, generating financial
consequences, insecurity and anxiety [11].
Advances have been made in the knowledge of COVID-19 and in the develop-
ment of safe and effective vaccines [12]. However, there is still no specific pharma-
cological protocol approved to prevent and/or reduce contamination by the virus, so
that there are countless ongoing researches to find an appropriate treatment [13].
The development of vaccines, convalescent plasma therapies, cell-based and mono-
clonal antibody therapies are some of the treatments studied worldwide. However,
the development of new drugs is a long and expensive process, and the current
health emergency has led to the use of existing drugs [14].
The pandemic has induced the global scientific community to focus efforts on
COVID-19 [15] and clinical trials represent the gold standard for evidence-based practice
[16], as they are importantmethods for assessing interventionmodalities, generating
impact on current and future clinical practice [17]. However, attention should be paid to
clinical trials with inadequate or low-quality designs, and it is important to analyze their
designs on clinical trial registration platforms to identify those that provide the best
scientific evidence that can reduce the effects of the COVID-19 pandemic [18].
In view of the fact that SARS-CoV-2 is a virus with characteristics never before
studied, with several consequences that go beyond contamination, and in the absence
of an approved effective therapy, correctly designed clinical trials are essential for
evaluating interventions in order to prevent and contain the spread of the disease.
Thus, the guiding issue that supported this chapter was: “Which interventions for use
in patients with COVID-19 are being evaluated by American researchers?”
2. Methods
The database chosen for this studywas the Clinical Trials platform (https://clinica
ltrials.gov/), which comprises a web-based resource that provides patients, their family
members, health care professionals, researchers, and the public with easy access to
information on publicly and privately supported clinical studies on a wide range of
diseases and conditions [19]. In the search strategy, keywords “COVID-19” in the
“Condition or Disease” section and “United States” in the “Country” sectionwere used.
No filters were applied, so that all registered clinical trials were analyzed. Data
were collected in March 2021 by a single previously trained researcher. Studies with
suspended, withdrawn and terminated recruitment status, observational and
expanded access studies, and those that did not mention COVID-19 diagnosis and
those including healthy patients among their eligibility criteria were excluded.
The following information was collected: study location, number of participants,
age groups of subjects (0–17, 18–64, >65), allocation (randomized, non-randomized
e n/a), intervention model (single group assignment, sequential assignment,
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crossover assignment, parallel assignment and factorial assignment), masking
(blind, double-blind, triple-blind, quadruple-blind and open label), purpose (diag-
nostic, treatment, prevention, basic science, supportive care, health services
research, device feasibility, screening and other), diagnostic criteria for COVID-19
(confirmed, suspect and confirmed or suspect), other eligibility criteria, recruit-
ment status (completed, recruiting, active, not recruiting, not yet recruiting and
enrolling by invitation), numbers of arms, type of intervention (dietary supple-
ment, drug, biological, device, diagnostic test, procedure, radiation, behavioral,
combination product and other), phase (early phase 1, phase 1, phase 2, phase 3,
phase 4, phase 1 and phase 2, phase 2 and phase 3 and n/a), presence of placebo (yes
and no), comparison arm (yes and no), and sponsor (university, pharmaceutical/
biotechnology company, research organizations, hospital, health care provider,
doctor, united states department of defense and philanthropy).
Types of intervention were classified according to the WHO’s Anatomical Ther-
apeutic Chemical Classification System [20]. In cases where they are not included in
the WHO’s ATC, information present on the companies’ websites was used.
Data were tabulated and analyzed using the Microsoft Excel 2016 for Windows
software (Microsoft Press, Redmond, WA, USA) and descriptively presented.
3. Results
In total, 5,129 records involving COVID-19 were found and, after the search
strategy, 1,182 (23%) corresponded to clinical trials developed in the United States.
Of these, eight studies that were suspended, 22 that had been withdrawn, 25 termi-
nated, 325 observational studies, 18 expanded access, 37 that did not include
COVID-19 diagnosis and, finally, 251 clinical trials using healthy patients were
excluded. At the end, 496 studies met the eligibility criteria and were selected.
The geographic distribution of studies highlights the state of California as the
main place for carrying out these surveys (155 studies), followed by Florida (124
studies), Texas (121 e studies), Nova York (115 studies), Illionois (86 studies),
Massachusetts (81 studies), Pennsylvania (78 studies), North Carolina (75 studies),
Washington and Ohio (73 studies each), Michigan (71 studies), Maryland (70 stud-
ies), Georgia (66 studies), Louisiana (64 studies), New Jersey (56 studies), Virginia
and Arizona (50 studies each), Minnesota (45 studies), Colorado (39 studies),
Alabama (38 studies), Tennessee (35 studies), Missouri (33 studies), Connecticut (30
studies), Utah (29 studies), Oregon (28 studies), South Carolina and Kansas (27
studies), Kentucky (25 studies), NewMexico and Nebraska (22 studies each), Indiana
and Iowa (21 studies), Wisconsin and Mississippi (20 studies each), Arkansas (16
studies), Idaho and Rhode Island (14 studies), Oklahoma (11 studies), West Virginia
(10 studies), Maine and South Dakota (9 studies each), Hawaii and Montana (7
studies each), Vermont (3 studies), and Alaska and Delaware (1 studies each).
The number of participants ranged from 1 to 10,000 individuals. Most clinical
trials analyzed involved adults and older adults, with higher percentage in the age
group of 18–64 years (48.6%), while surveys that recruited children and adolescents
represented only 2.9%.
Regarding the allocation of participants, only 26 studies (5.2%) were not char-
acterized as randomized. The most frequent intervention model is the parallel
(75.6%). Regarding the type of masking, the open study model (38.7%) is the most
prevalent, followed by the double-blind model (21.4%), while single-blind studies
corresponded to only 4.4%. Studies with therapeutic purposes were carried out in
the majority (88.3%) and there is predominance of those who consider proven and
positive COVID-19 diagnosis (89.1%) as an inclusion criterion (Table 1).
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Variables n %
Age Groups (in years)*
0–17 29 2.9
18–64 489 48.6






Single Group Assigment 86 17.3
Sequential Assignment 26 5.2
Crossover Assignment 3 0.6
Parallel Assignment 375 75.6











Basic Science 2 0.4
Supportive Care 17 3.4
Health Services Research 2 0.4
Device Feasibility 2 0.4
Screening 1 0.2
Other 7 1.4
Diagnostic Criteria for COVID-19
Confirmed 442 89.1
Suspect 11 2.2




Active, not recruiting 68 13.7
Not yet recruiting 50 10.1
Enrolling by invitation 17 3.4
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No information 1 0.2
Type of Intervention*








Combination Product 3 0.6
Other 28 5.4
Phase





1 e 2 35 7.1










No information 1 0.5
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Other eligibility criteria used by researchers were the inclusion of individuals
with associated risk factors (28 studies), including cancer (4 studies), type 1 or type
2 diabetes mellitus (3 studies) and heart diseases (1 study).
Regarding recruitment status, at the time of data collection, 59.5% of clinical trials
were recruiting participants and 13.7% were active, but not recruiting. Regarding the
number of arms, most studies use the two-arm test (67.3%). Most clinical trials
research a new drug (64.8%), are in phase 2 (43.2%), 55.2% use placebo and 54.5%
use comparison arm. As for sponsors, pharmaceutical/biotechnology companies
(35.4%) and universities (29.4%) are those that most invest in clinical trials (Table 1).
Regarding the identification and classification of drugs, biological interventions,
dietary supplements, combined products and some other interventions, 434 clinical
trials use interventions in monotherapy and 67 make use of combinations. In
monotherapy, most trials assess immunosuppressants (49 studies), followed by
COVID-19 Convalescent Plasma (40 studies), antivirals (32 studies), anticancer (30
studies), antithrombotic (24 studies), anti-inflammatory agents (16 studies),
antifibrinolytics (14 studies), antimalarials (13 studies), immunostimulants (7
studies), expectorants (6 studies), antibacterials (5 studies), antiparasitic and
corticosteroids (4 studies each), antidepressants (3 studies), sex hormones and
modulators of the genital system (2 studies) and antiprotozoals (1 study)
(Tables 2 and 4). Clinical trials using combinations use antivirals /immunosup-
pressants (9 studies), antimalarials /antibiotics (6 studies), antithrombotic agents




Pharmaceutical / Biotechnology Company 242 35.4
Research Organizations 65 9.5
Hospital 82 12.0
Health Care Provider 39 5.7
Doctors 36 5.2
United States Department of Defense 6 0.9
Philanthropy 13 1.9
*Some studies involved more than one age group, type of intervention and sponsor; N/a = Not applicable.
Table 1.





n* Interventions and Classes n*
Antithrombotic
Agents
24 Interferon 4 AZD7442 2




Enoxaparin 4 Sargramostim 1 Zinc 2
Apixaban 3 Anticancer 30 IVIG 2
Defibrotide 2 Colchicine 5 Octagam 2
Rivaroxaban 2 Ibrutinib 3 GAMUNEX-C 1
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n* Interventions and Classes n*
Dipyridamole 2 CYT107 2 Garadacimab 1
Tenecteplase 2 Duvelisib 2 Sodium bicarbonate 1
Acetylsalicylic Acid 1 Ruxolitinib 1 NasoVAX 1
VentaProst 1 Abivertinib 1 NA-831 1
TM5614 1 Pacritinib 1 Ifenprodil 1
Antifibrinolytics 14 Decitabine 1 ABBV-2B04 1
Camostat 9 Bempegaldesleukin 1 ABBV-47D11 1
Tranexamic acid 2 Etoposide 1 Ibudilast 1
Ulinastatin 1 Bicalutamide 1 MAS825 1
LYT-100 1 Imatinib 1 BGB-DXP593 1
BLD-2660 1 Upamostat 1 PUL-042 1
Antimalarials 13 Nintedanib 1 PurCo 1
Chloroquine or
hydroxychloroquine
11 Acalabrutinib 1 Bucillamine 1
Tafenoquine 1 Degarelix 1 Pioglitazone 1
Artesunate 1 Antroquinonol 1 Gimsilumab 1
Antivirals 24 Selinexor 1 BI 764198 1
Molnupiravir 4 Zanubrutinib 1 Zilucoplan 1
Favipiravir 3 FT516 1 Lanadelumab 1
Lopinavir/Ritonavir 2 CYNK-001 1 rNAPc2 1
Brequinar 2 Antiparasitic 4 Aprepitant 1
Silmitasertib 2 Ivermectin 2 Brexanolone 1
Apilimod Dimesylate 1 Niclosamide 1 Pepto Bismol 1
Maraviroc 1 Disulfiram 1 Ruconest 1
Liquid Alpha1-
Proteinase Inhibitor
1 Antiprotozoals 1 Isavuconazonium 1
RBT-9 1 Atovaquone 1 Fostamatinib 1
AT-527 1 Corticosteroids 4 VIB7734 1
BTL-TML-COVID 1 Dexamethasone 2 Pamrevlumab 1
LAU-7b 1 Ciclesonide 1 CAP-1002 1
Veru-111 1 Prednisone 1 Linagliptin 1
PTC299 1 Anti-inflammatory 16 CM4620-IE 1
PF-07304814 1 Acebilustat 2 Vadadustat 1
RTB101 1 Ampion 2 Zofin 1
Antibacterials 5 N-acetyl glucosamine 1 ADG20 1
Azithromycin 2 Alvelestat 1 GC4419 1
Doxycycline 1 Dociparstat 1 Essential Oil Blend 1
Brilacidin 1 Ensifentrine 1 Fenofibrate 1
Carrimycin 1 Bardoxolone Methyl 1 ATI-450 1
Antidepressants 3 Indomethacin 1 Xuanfei Baidu Granules 1
Fluvoxamine 2 EDP1815 1 Emricasan 1
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n* Interventions and Classes n*
Fluoxetine 1 LSALT peptide 1 ORTD-1 1
Immunosuppressants 49 OP-101 1 Metformin 1
Tocilizumab 7 FSD201 1 Umbilical Cord Lining Stem Cells 1
Anakinra 3 RLS-0071 1 BGE-175 1
Cyclosporine 2 ST266 1 Chlorine dioxide 1




Ravulizumab 2 Estradiol 1 Cetylpyridinium Chloride 1
Sarilumab 2 Progesterone 1 Peroxil 1
Leflunomide 2 Expectorants
(mucolytics)
6 Colgate Total Zero 1
Razuprotafib 1 N-acetylcysteine 3 Saline rinse 1
Dapansutrile 1 Pulmozyme 2 Crizanlizumab 1
Abatacept 1 Dornase Alfa 1 AT-001 1




Olokizumab 1 Mesenchymal stem cells
(MSCs)
11 Glycine 1
Infliximab 1 Nitric Oxide 7 Alanine 1
Tociliuzumab 1 Cytotoxic T
Lymphocytes
7 Thymalfasin 1
Canakinumab 1 Bamlanivimab 6 TB006 1
Sirukumab 1 Clazakizumab 6 PF-06650833 1
Lenzilumab 1 Chlorhexidine 5 Angiotensin 1
Otilimab 1 Vitamin D 4 Tradipitant 1
Tofacitinib 1 Vitamin C 4 Resistant starch 1
Auxora 1 Mavrilimumab 4 F-652 1
APL-9 1 Povidone Iodine 4 Omega-3 1
CD24Fc 1 Fisetin 3 L-Citrulline 1
TL-895 1 Leronlimab 3 FoTv 1
TD-0903 1 Listerine 3 VisAcT 1
EB05 1 Hydrogen Peroxide 3 Regadenoson 1
ATYR1923 1 Famotidine 2 Sulfur hexafluoride lipid-type A 1
CERC-002 1 Melatonin 2 Lucinactant 1
M5049 1 VIR-7831 2 CBDRA60 1
BMS-986253 1 Nitrogen gas 2 SBI-101 1
GLS-1027 1 NT-I7 2 Zavegepant 1
UTTR1147 1 Betadine 2 Neuromuscular Blocking Agents 1
MSTT1041A 1 Naltrexone 2 Artemesia annua 1
TJ003234 1 Human Amniotic Fluid 2 Nerium oleander 1
8





n* Interventions and Classes n*
Immunostimulants 7 KB109 2
*Some studies used several interventions.
The bold entries refer to the drug classes and the total interventions of each class of drugs and biological products
according to the WHO’s Anatomical Therapeutic Chemical Classification System or information present on the
companies’ websites.
Table 2.
Monotherapy interventions used in experimental groups of registered clinical trials on COVID-19.
Interventions and Classes n*
Antithrombotic Agents Combinations 4
Heparin + P2Y12 2
Dipyridamole + Acetylsalicylic Acid 1
Enoxaparin + Heparin + Fondapariniux + Argatroban 1
Antimalarials + Antibiotics 6
Hydroxychloroquine + Azithromycin 6
Antivirals + Immunosuppressants 7
Remdesivir + Tocilizumab 1
Remdesivir + Infliximab 1
Remdesivir + Apremilast 1
Remdesivir + Abatacept 1
Remdesivir + Risankizumab 1
Remdesivir + Apremilast 1
Remdesivir + Lenzilumab 1
Antivirals + Corticosteroids 2
Atazanavir + Dexamethasone 1
Remdesivir + Dexamethasone 1
Other Combinations 41
Remdesivir + Cenicriviroc 2
Valproate + Quetiapine 1
PurInf (I) + PurInf (II) + PurInf (III) 1
PurPhl + PurClo 1
Colchicine + Rosuvastatin 1
Colchicine + Naltrexone 1
Naltrexone + Ketamine 1
BRII-196 + BRII-198 1
NA-831 + Dexamethasone 1
NA-831 + Atazanavir 1
IVIG + Remdesivir 1
Rintatolimod +Interferon 1
Remdesivir + Interferon 1
Remdesivir + Icatibant 1
Remdesivir + Razuprotafib 1
Remdesivir + anti-CD14 1
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Interventions and Classes n*
Plasma + Ruxolitinib 1
Bamlanivimab + VIR-7831 1
ABBV-47D11 + ABBV-2B04 1
Mesenchymal Stem Cells + Heparin 1
Metformin + Naltrexone 1
Resveratrol + Vitamin D 1
Nitazoxanide + Vitamin Super B-Complex 1
Vitamin C + Zinc 1
Resveratrol + Zinc 1
Famotidine + N-Acetyl cysteine 1
Chlorine dioxide + Zinc acetate 1
Atovaquone + Azithromycin 1
Camostat Mesilat + Bicalutamide 1
Xylitol + Grapefruit Seed Extract 1
Peroxil + Chlorhexidine 1
Hydroxychloroquine + Azithromycin + Zinc 1
Hydroxychloroquine + Zinc + Doxycycline 1
Hydroxychloroquine + Nitazoxanide + Ribavirin 1
Hydroxychloroquine + Azithromycin + Ritonavir + Lopinavir 1
Bamlanivimab + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 1
Chlorine dioxide + Famotidine + Lactoferrin + green tea extract 1
Chlorine dioxide + Zinc acetate + Famotidine + Lactoferrin + green tea extract 1
Hydroxychloroquine + Azithromycin + Vitamin C + Vitamin D + Zinc 1
Ivermectin + Doxycycline Hc + Vitamin C + Vitamin D + Zinc 1
*Some studies used several interventions.
Table 3.
Combinations of interventions used in experimental groups of registered clinical trials on COVID-19.
Interventions and Classes n*
COVID-19 Convalescent Plasma 40
Antivirals 8
Remdesivir 8
Antivirals + Immunosuppressants 2
Remdesivir + Baricitinib 2
Other Combinations 5
Bamlanivimab + Etesevimab 2
REGN10933 + REGN10987 3
*Some studies used several interventions.
The bold entries refer to the drug classes and the total interventions of each class of drugs and biological products according to
the WHO’s Anatomical Therapeutic Chemical Classification System or information present on the companies’ websites.
Table 4.
Monotherapy and combinations of interventions with Emergency Use Authorizations (EUA) issued by U.S.
Food and Drug Administration (FDA) used in experimental groups of registered clinical trials on COVID-19.
10
Science-Based Approaches to Respond to COVID and Other Public Health Threats
4. Discussion
Many clinical trials related to the COVID-19 pandemic have emerged in
response to society’s concerns related to the impacts of the pandemic, and in
response to this global emergency. Scientific production on the topic is dynamic and
fast, which makes the sharing and synthesis of knowledge important [15]. In this
context, the characterization of research efforts can help professionals, researchers,
and managers to understand the relevant aspects of the disease.
Considering the serious public health crisis of COVID-19 and the search for
discovering safe and effective treatments, high-quality research is needed to evaluate
interventions for the prevention of the disease and its treatment. Clinical trials prop-
erly designed and conducted make their results valid and can significantly contribute
to the effort to improve the effectiveness and efficiency of health interventions [21].
“Clinical Trials” is a robust platform for registering clinical trials, containing
detailed information on a large amount of clinical research conducted in 219 coun-
tries [22]. According to the Dimensions database, “Clinical Trials” is the leading
platform for registering clinical trials on COVID-19, accounting for 58.8% of all
registrations [23]. Of the clinical trials registered and found on this platform, a
significant number is being developed by American researchers. This research
leadership is underpinned by huge public funding, mainly from the National Insti-
tutes of Health (NIH), which has already received more than US$ 3.6 billion to fund
research on COVID-19 [24], as well as from government agencies, universities and
the private sector [25], which demonstrates the urgency of the USA in the face of
the severity with which the disease reached the country [18].
Among studies analyzed, the majority of participants are adults and older adults.
It is known that COVID-19 is less prevalent in children compared to adults and
adolescents and that younger individuals infected with SARS-CoV-2 have less
severe symptoms and lower hospitalization and lethality rates [26, 27]. In March 31,
2021, 11.7% of COVID-19 cases in the United States were of children and adoles-
cents up to 17 years of age, corresponding to almost 3 million cases. Of these, for the
age group of 0–4 years, there were only 104 deaths (<0.01%) and, for the age
group of 5–17 years, only 228 deaths (0.1%) [27]. Therefore, these may be the
reasons for choosing the age group of adults and older adults.
The most frequent study design was randomized allocation, the parallel inter-
vention model and the open masking type. The randomization of a clinical trial
ensures that, in addition to intervention, there are no systematic differences
between study groups, providing impartial results regarding the effect of interven-
tions and reducing biases [18, 28]. Even so, only randomization does not exclude
the possibility of systematic differences, because since those involved in a clinical
trial are aware of the attributions of interventions, which can influence the result
and introduce bias [29]. In our study, masking was not feasible mainly for ethical
reasons or because patients are incorporated into healthcare environments, making
it difficult to blind the team that manages patient care [30].
There were greater number of clinical trials for therapeutic purposes that evalu-
ate some drug as a type of intervention. These results may be related to the current
world scenario and the urgent need for studies analyzing which treatments are
shown to be most effective against COVID-19 [18] in an adequate and quick man-
ner. The discovery of an efficient therapy would allow the prophylaxis of health
professionals who are on front lines, so that they could get back to work more
quickly, in addition to reducing the time spent by critically ill patients in intensive
care units, freeing beds [31] and reducing mortality rates. Many studies using a
placebo group were also found, and due to the lack of approved available treatment,
this procedure is ethically acceptable [18].
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In this study, the most frequent sponsors were pharmaceutical/biotechnology
companies and universities. However, in the evaluated clinical trials, there was the
collaboration of several companies, academic institutions, government agencies,
non-profit organizations and individual medical researchers to properly implement
resources in the fight against COVID-19 in order to concentrate and accelerate the
development and implementation of therapies. This partnership of efforts may
reflect the so-called Accelerating COVID-19 Therapeutic Interventions and Vac-
cines (ACTIV), conducted by NIH and announced in April 2020, in which
researchers continue to work intensively to develop new and better treatments [32].
Regarding the classification of many tested drugs, biological interventions, die-
tary supplements, combined products and some other types of intervention, het-
erogeneity of classes used can be observed. Most clinical trials have been evaluated
immunosuppressants or combinations of antivirals/immunosuppressants, some
already with USA issued by the FDA and redirected for the treatment of COVID-19,
such as the combination of immunosuppressant Baricitinib – used to treat rheuma-
tological diseases [33] – with antiviral Remdesivir – used to treat patients infected
with the Ebola virus, MERS-CoV and SARS-CoV-1 [34], and its use as monotherapy
for certain patients hospitalized with COVID-19.
Other authorized drugs that deserve mention are the biological products
Bamlanivimab and Etesevimab – neutralizing IgG1 monoclonal antibodies that bind
to different but overlapping epitopes in the binding domain to the SARS-CoV-2
spike protein [35] –, REGEN-COV (Casirivimab and Imdevimab) – neutralizing
recombinant human IgG1 monoclonal antibodies that target the binding domain to
the SARS-CoV-2 spike protein receptor [36] –, and the COVID-19 convalescent
plasma – collected from individuals whose plasma contains anti-SARS-CoV-2 anti-
bodies [37].
The COVID-19 pathogenesis begins with the replication of SARS-CoV-2, subse-
quently followed by an exaggerated immune /inflammatory response to the virus
that leads to tissue damage. Regarding this knowledge, it is assumed that antiviral
therapies would have greater effect early in the course of the disease, whereas
immunosuppressive/anti-inflammatory therapies may be more beneficial in later
stages of COVID-19 [33]. The use of these existing drugs helps reducing the cost and
time of research; however, further large-scale studies must be carried out to assess
the benefits and safety of these drugs.
The findings reported here make it clear that researchers from different fields of
medicine have worked together in the development and clinical evaluation of sev-
eral drugs aimed at treating the numerous medical complications caused by
COVID-19. Extensive financial resources, made available by universities and phar-
maceutical and biotechnology companies, have been applied in order to allow the
conduction of clinical trials with high methodological and scientific rigor for both
diagnostic and treatment purposes. Undeniably, the emergency approval of the
tested drugs described here by the FDA, while making it possible to save thousands
of lives in the American territory, has allowed a better understanding of their
effects on individuals affected by COVID-19, which knowledge has been shared and
put into practice by managers and medical teams from various countries around the
world.
Therefore, during the COVID-19 pandemic and due to all resulting restrictions
and difficult circumstances, good scientific practice and data transparency are
essential principles that should guide the conduction of clinical trials. The sharing of
these results, when properly carried out, helps professionals to make decisions, as
well as researchers to identify gaps and more promising interventions, to avoid
research waste and to expose patients to unnecessary risks, consequently contrib-
uting to the advancement of scientific knowledge.
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5. Conclusion
Clinical trials developed by American researchers involving COVID-19 include
adult and elderly participants, with predominance of randomized, parallel and open
design, those for therapeutic purposes and those that mostly evaluate immunosup-
pressants or combinations of antivirals/immunosuppressants. The drugs and bio-
logical products Remdesivir, Baricitinib in combination with Remdesivir,
Bamlanivimab and Etesevimab, REGEN-COV and COVID-19 convalescent plasma
were also used, authorized for emergency use.
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